Literature DB >> 16629824

Mechanism of action and structural requirements of constrained peptide inhibitors of RGS proteins.

Rebecca A Roof1, Yafei Jin, David L Roman, Roger K Sunahara, Masaru Ishii, Henry I Mosberg, Richard R Neubig.   

Abstract

Regulators of G-protein signaling (RGS) accelerate guanine triphosphate hydrolysis by Galpha-subunits and profoundly inhibit signaling by G protein-coupled receptors. The distinct expression patterns and pathophysiologic regulation of RGS proteins suggest that inhibitors may have therapeutic potential. We previously reported the design of a constrained peptide inhibitor of RGS4 (1: Ac-Val-Lys-[Cys-Thr-Gly-Ile-Cys]-Glu-NH2, S-S) based on the structure of the Galphai switch 1 region but its mechanism of action was not established. In the present study, we show that 1 inhibits RGS4 by mimicking and competing for binding with the switch 1 region of Galphai and that peptide 1 shows selectivity for RGS4 and RGS8 versus RGS7. Structure-activity relationships of analogs related to 1 are described that illustrate key features for RGS inhibition. Finally, we demonstrate activity of the methylene dithioether-bridged peptide inhibitor, 2, to modulate muscarinic receptor-regulated potassium currents in atrial myocytes. These data support the proposed mechanism of action of peptide RGS inhibitors, demonstrate their action in native cells, and provide a starting point for the design of RGS inhibitor drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629824     DOI: 10.1111/j.1747-0285.2006.00373.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  15 in total

1.  Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986.

Authors:  David L Roman; Levi L Blazer; C Aaron Monroy; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2010-06-07       Impact factor: 4.436

2.  Microfabricated channel array electrophoresis for characterization and screening of enzymes using RGS-G protein interactions as a model system.

Authors:  Jian Pei; John F Dishinger; David L Roman; Chetwana Rungwanitcha; Richard R Neubig; Robert T Kennedy
Journal:  Anal Chem       Date:  2008-05-09       Impact factor: 6.986

3.  Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction.

Authors:  David L Roman; John R Traynor
Journal:  J Med Chem       Date:  2011-09-29       Impact factor: 7.446

Review 4.  The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21.

Authors:  B Sjögren
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

5.  Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins.

Authors:  Levi L Blazer; David L Roman; Alfred Chung; Martha J Larsen; Benjamin M Greedy; Stephen M Husbands; Richard R Neubig
Journal:  Mol Pharmacol       Date:  2010-06-22       Impact factor: 4.436

Review 6.  Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials.

Authors:  Joseph B O'Brien; Joshua C Wilkinson; David L Roman
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.157

7.  Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.

Authors:  Jeffery N Talbot; David L Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard R Neubig; John R Traynor
Journal:  J Neurochem       Date:  2009-11-30       Impact factor: 5.372

8.  Polyplexed flow cytometry protein interaction assay: a novel high-throughput screening paradigm for RGS protein inhibitors.

Authors:  David L Roman; Shodai Ota; Richard R Neubig
Journal:  J Biomol Screen       Date:  2009-06-16

9.  Regulator of G protein signaling protein suppression of Galphao protein-mediated alpha2A adrenergic receptor inhibition of mouse hippocampal CA3 epileptiform activity.

Authors:  Brianna L Goldenstein; Brian W Nelson; Ke Xu; Elizabeth J Luger; Jacquline A Pribula; Jenna M Wald; Lorraine A O'Shea; David Weinshenker; Raelene A Charbeneau; Xinyan Huang; Richard R Neubig; Van A Doze
Journal:  Mol Pharmacol       Date:  2009-02-18       Impact factor: 4.436

10.  A covalent peptide inhibitor of RGS4 identified in a focused one-bead, one compound library screen.

Authors:  Rebecca A Roof; David L Roman; Samuel T Clements; Katarzyna Sobczyk-Kojiro; Levi L Blazer; Shodai Ota; Henry I Mosberg; Richard R Neubig
Journal:  BMC Pharmacol       Date:  2009-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.